GlassScriptPhysician profile
Jose A Quiros
NPI 1902874357
$4,413.42
in general payments reported to CMS, 2019-2025
28 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $554 · 2021: $449 · 2022: $357 · 2023: $565 · 2024: $307 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $484.89 | 2019-2022 | |
| Amgen INC. | $450.10 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $427.19 | 2019-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $321.82 | 2019-2022 | |
| Allergan, INC. | $310.33 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $276.17 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.41 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.57 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $238.85 | 2023-2025 | Rexulti |
| Insmed, INC. | $219.72 | 2019-2021 | |
| Lilly USA, LLC | $208.74 | 2019-2023 | Mounjaro |
| Abbvie INC. | $142.47 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $132.88 | 2023 | |
| Glaxosmithkline, LLC. | $116.67 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $94.63 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $73.70 | 2019 | |
| Amarin Pharma, INC. | $61.97 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $57.81 | 2019-2023 | Ztlido |
| Pfizer INC. | $54.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.15 | 2019 | |
| Medicure Pharma INC. | $34.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.38 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $15.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.08 | 2020 | |
| Irhythm Technologies, INC. | $12.37 | 2019 | |
| Aytu Biopharma, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Quiros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.